Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes

Neurology

Volumn 85, Issue 13, 2015, Pages 1131-1138

  Espeland, Mark A ^a   Brinton, Roberta Diaz ^b   Manson, Joann E ^c   Yaffe, Kristine ^d   Hugenschmidt, Christina ^a   Vaughan, Leslie ^a   Craft, Suzanne ^a   Edwards, Beatrice J ^e   Casanova, Ramon ^a   Masaki, Kamal ^f   Resnick, Susan M ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of Southern California   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF HAWAII   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; INSULIN; MEDROXYPROGESTERONE ACETATE; ORAL ANTIDIABETIC AGENT; PLACEBO;

AGED; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN SIZE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; FOLLOW UP; GRAY MATTER; HIPPOCAMPUS; HORMONAL THERAPY; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; WHITE MATTER; ADVERSE EFFECTS; DRUG EFFECTS; ESTROGEN THERAPY; PATHOLOGY;

AGED; DIABETES MELLITUS, TYPE 2; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; GRAY MATTER; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84940778472     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001816     Document Type: Article

References (40)

1. Carcaillon L, Brailly-Tabard S, Ancelin ML, et al. High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology 2014;82: 504-511.
2. Rolandsson O, Backestrom A, Eriksson S, Hallmans G, Nilsson LG. Increased glucose levels are associated with episodic memory in nondiabetic women. Diabetes 2008; 57:440-443.
3. Dahle CL, Jacobs BS, Raz N. Aging, vascular risk and cognition: blood glucose, pulse pressure, and cognitive performance in healthy adults. Psychol Aging 2009;24: 154-162.
4. Yaffe K, Barnes D, Lindquist K, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007;28:171-178.
5. Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study. Clin Endocrinol (Oxf) 2010;72:99-106.
6. Geerlings MI, Launer LJ, de Jong FH, et al; Rotterdam Study. Endogenous estrogen and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 2003;53:607-615.
7. Espeland MA, Miller ME, Goveas JS, et al; Whisca Study Group. Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women's health initiative study of cognitive aging. J Womens Health (Larchmt) 2011;20:1435-1443.
8. Espeland MA, Bryan RN, Goveas JS, et al; WHIMS-MRI Study Group. Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. Diabetes Care 2013;36:90-97.
9. Shumaker SA, Legault C, Kuller L, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
10. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in post-menopausal women. JAMA 2004;291:2959-2968.
11. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmen-opausal hormone therapy and regional brain volume: the WHIMS-MRI Study. Neurology 2009;72:135-142.
12. Espeland MA, Tindle HA, Bushnell CA, et al. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci 2009;64:1243-1250.
13. Casanova R, Espeland MA, Goveas JS, et al; Women's Health Initiative Memory Study. Application of machine learning methods to describe the effects of conjugated equine estrogens on region-specific brain volumes. Magn Reson Imaging 2011;29:546-553.
14. Coker LH, Espeland MA, Hogan PE, et al; WHIMS-MRI Study Group. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology 2014;82:427-434.
15. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998;19:604-621.
16. Jaramillo SA, Felton D, Andrews LA, et al; Women's Health Initiative Memory Study Research Group. Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study. Acad Radiol 2007;14:603-612.
17. Margolis KL, Qi L, Brzyski R, et al; Women Health Initiative Investigators. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240-247.
18. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
19. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-318.
20. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955-959.
21. Lao Z, Shen D, Liu D, et al. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol 2008;15:300-313.
22. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology 2009;72:125-134.
23. Launer LJ, Miller ME, Williamson JD, et al; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011;10:969-977.
24. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc.; 1996.
25. Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013;20:695-709.
26. Wnuk A, Korol DL, Erickson KI. Estrogens, hormone therapy, and hippocampal volume in postmenopausal women. Maturitas 2012;73:186-190.
27. Rasgon NL, Kenna HA, Wroolie TE, et al. Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy. Psychiatr Res 2014;223: 28-36.
28. Espeland MA, Shumaker SA, Leng I, et al; WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173: 1429-1436.
29. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Instit 1995;87:1297-1302.
30. Driscoll I, Espeland MA, Wassertheil-Smoller S, et al; Women's Health Initiative Study of Cognitive Aging. Weight change and cognitive function: findings from the Women's Health Initiative Study of Cognitive Aging. Obesity (Silver Spring) 2011;19:1595-1600.
31. Ryan J, Artero S, Carriere I, et al. Brain volumes in late life: gender, hormone treatment, and estrogen receptor variants. Neurobiol Aging 2014;35;645-654.
32. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036-4042.
33. Manschot SM, Biessels GJ, de Valk H, et al; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007;50: 2388-2397.
34. Williamson JD, Miller ME, Bryan RN, et al; ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007;99:112i-122i.
35. Willette AA, Xu G, Johnson SC, et al. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 2013;36:443-449.
36. Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol 2014;35:8-30.
37. Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev 2008;60:1504-1511.
38. Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008;31:529-537.
39. Bansal S, Chopra K. Distinct role of estrogen receptor-alpha and beta on postmenopausal diabetes-induced vascular dysfunction. Gen Compar Endocrinol 2014; 206:51-59.
40. Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Estrogen restores brain insulin sensitivity in ovariecto-mized non-obese rats, but not in ovariectomized obeserats. Metabolism 2014;63:851-859.